08.08.19: Bayer acquires BlueRock Therapeutics to build leading position in cell therapy

Bayer acquires BlueRock Therapeutics to build leading position in cell therapyImplied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer / Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson's disease expected later this year / BlueRock Therapeutics to continue to operate as an independent companymehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news